Innovative therapeutics

Investors

IR Snapshot

NASDAQBMRN
Beta1.37
Shares Outstanding179.6M
Average Volume (10 days)951.1K
Qtrly Dividend (Ann. Yield)-- (--)

Per Share Data

Earnings (TTM)($0.25)
Sales (TTM)$6.96
Book Value (MRQ)$17.12
Cash Flow (TTM)$0.23
Cash (MRQ)$4.02

Analyst Views

Current Mean RecommendationStrong Buy
Strong Buy15
 
Buy2
 
Hold3
 
Underperform0
 
Sell0
 

Recent Insider Transactions

Jean-Jacques Bienaime
Director, Chief Executive Officer
(10,000)
Sell
Feb 3, 2020
Jean-Jacques Bienaime
Director, Chief Executive Officer
(8,000)
Sell
Jan 14, 2020
Jean-Jacques Bienaime
Director, Chief Executive Officer
(4,000)
Sell
Jan 8, 2020
Jean-Jacques Bienaime
Director, Chief Executive Officer
(3,000)
Sell
Jan 7, 2020
Jean-Jacques Bienaime
Director, Chief Executive Officer
(5,000)
Sell
Dec 27, 2019

Recent SEC Filings

Amended >= 5% Acquisition
Feb 14, 2020
5
Feb 13, 2020
Amended >= 5% Acquisition
Feb 12, 2020
Amended >= 5% Acquisition
Feb 12, 2020
Amended >= 5% Acquisition
Feb 10, 2020

BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI, CLN2 disease) PKU, LEMS

Products

Palynziq®
Brineura®
Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information